loading
Schlusskurs vom Vortag:
$0.865
Offen:
$0.86
24-Stunden-Volumen:
141.12K
Relative Volume:
0.05
Marktkapitalisierung:
$5.76M
Einnahmen:
$644.60K
Nettoeinkommen (Verlust:
$-9.87M
KGV:
-0.00102
EPS:
-837.9618
Netto-Cashflow:
$-9.02M
1W Leistung:
-6.67%
1M Leistung:
-20.41%
6M Leistung:
-78.78%
1J Leistung:
-96.15%
1-Tages-Spanne:
Value
$0.845
$0.8601
1-Wochen-Bereich:
Value
$0.8308
$0.97
52-Wochen-Spanne:
Value
$0.7846
$41.50

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile

Name
Firmenname
Biodexa Pharmaceuticals Plc Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
13
Name
Twitter
Name
Nächster Verdiensttermin
2024-06-13
Name
Neueste SEC-Einreichungen
Name
BDRX's Discussions on Twitter

Vergleichen Sie BDRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BDRX
Biodexa Pharmaceuticals Plc Adr
0.8576 5.76M 644.60K -9.87M -9.02M -837.96
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
454.86 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
544.89 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.40 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
553.72 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.78 28.51B 3.81B -644.79M -669.77M -6.24

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-02-08 Eingeleitet Ladenburg Thalmann Buy

Biodexa Pharmaceuticals Plc Adr Aktie (BDRX) Neueste Nachrichten

pulisher
Jun 18, 2025

Biodexa enrolls first patient in type 1 diabetes drug trial - Investing.com

Jun 18, 2025
pulisher
Jun 13, 2025

Biodexa Pharmaceuticals changes share nominal value By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Biodexa Pharmaceuticals changes share nominal value - Investing.com

Jun 13, 2025
pulisher
Jun 11, 2025

Biodexa shareholders approve all resolutions at general meeting By Investing.com - Investing.com India

Jun 11, 2025
pulisher
Jun 11, 2025

Biodexa shareholders approve all resolutions at general meeting - Investing.com

Jun 11, 2025
pulisher
May 22, 2025

Biodexa secures additional $3M for cancer drug trial By Investing.com - Investing.com India

May 22, 2025
pulisher
May 22, 2025

BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Biodexa secures additional $3M for cancer drug trial - Investing.com

May 22, 2025
pulisher
May 20, 2025

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here - sharewise

May 20, 2025
pulisher
May 20, 2025

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Nasdaq

May 20, 2025
pulisher
May 15, 2025

Biodexa Pharmaceuticals adjusts warrant exercise price - Investing.com

May 15, 2025
pulisher
May 15, 2025

Biodexa Pharmaceuticals adjusts warrant exercise price By Investing.com - Investing.com India

May 15, 2025
pulisher
May 12, 2025

Biodexa gains orphan drug status in EU for colon disease treatment - Investing.com

May 12, 2025
pulisher
Apr 24, 2025

What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - MSN

Apr 24, 2025
pulisher
Mar 19, 2025

Biodexa Pharmaceuticals advances FAP treatment trial By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Biodexa Pharmaceuticals advances FAP treatment trial - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - BioSpace

Mar 19, 2025
pulisher
Mar 10, 2025

Biodexa gets FDA nod for Phase 3 eRapa study in FAP - Investing.com India

Mar 10, 2025
pulisher
Mar 07, 2025

Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday - Yahoo Finance

Mar 07, 2025
pulisher
Mar 06, 2025

Biodexa selects Precision as CRO for eRapa Phase 3 study in Europe - Investing.com

Mar 06, 2025
pulisher
Feb 12, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Barchart

Feb 12, 2025
pulisher
Feb 11, 2025

Biodexa Pharmaceuticals Plc ADR [BDRX] Is Currently 31.94 above its 200 Period Moving Avg: What Does This Mean? - The DBT News

Feb 11, 2025
pulisher
Feb 10, 2025

why Teva- Pharmaceutical Industries Ltd. ADR [TEVA] is a Good Choice for Investors After New Price Target of $24.71 - The DBT News

Feb 10, 2025
pulisher
Feb 10, 2025

Palantir Technologies Inc [PLTR] Is Currently -0.39 below its 200 Period Moving Avg: What Does This Mean? - The DBT News

Feb 10, 2025
pulisher
Feb 10, 2025

Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle

Feb 10, 2025
pulisher
Feb 10, 2025

Hesai Group ADR (HSAI) Shares Up Despite Recent Market Volatility - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Biodexa Pharmaceuticals Plc ADR (BDRX) vs. Its Peers: A Comparison - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Omega Therapeutics Inc (OMGA) Stock: A SWOT Analysis - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

AES Corp (AES) Shares Down Despite Recent Market Volatility - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Altus Power Inc (AMPS) vs. Its Peers: A Comparison - The News Heater

Feb 10, 2025
pulisher
Jan 30, 2025

Skechers (SKX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Jan 30, 2025
pulisher
Jan 30, 2025

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Jan 30, 2025
pulisher
Jan 14, 2025

Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance

Jan 14, 2025
pulisher
Jan 03, 2025

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Moves to Buy: Rationale Behind the Upgrade - MSN

Jan 03, 2025
pulisher
Dec 29, 2024

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN

Dec 29, 2024
pulisher
Nov 22, 2024

Result of General Meeting - GlobeNewswire

Nov 22, 2024
pulisher
Nov 12, 2024

Biodexa Pharmaceuticals regains Nasdaq compliance - Investing.com

Nov 12, 2024
pulisher
Oct 17, 2024

Biodexa reports promising glioblastoma trial results - Investing.com

Oct 17, 2024
pulisher
Oct 15, 2024

Biodexa Announces Successful Appeal of Nasdaq Delisting - GlobeNewswire

Oct 15, 2024
pulisher
Oct 04, 2024

Biodexa reports survival rates in glioblastoma study - Investing.com

Oct 04, 2024
pulisher
Sep 19, 2024

ADR Ratio Change - Yahoo Finance

Sep 19, 2024
pulisher
Jul 17, 2024

BDRX Stock Price and Chart — NASDAQ:BDRX - TradingView

Jul 17, 2024
pulisher
Mar 01, 2024

PRFX Stock Quote Price and Forecast - CNN

Mar 01, 2024
pulisher
Feb 09, 2024

symbol__ Stock Quote Price and Forecast - CNN

Feb 09, 2024
pulisher
Dec 19, 2023

Why Biodexa Pharmaceuticals (BDRX) Shares Are Getting Hammered - TradingView

Dec 19, 2023
pulisher
Jul 05, 2023

Biodexa Pharmaceuticals will rise 8,000% at the open - Dhaka Tribune

Jul 05, 2023
pulisher
Jun 27, 2023

Biodexa Pharma (BDRX) Stock Rallied 27% on Investor Interest - AskTraders.com

Jun 27, 2023
pulisher
Jun 23, 2023

Why Virgin Galactic Are Trading Lower By Around 18%; Here Are 20 Stocks Moving Premarket - markets.businessinsider.com

Jun 23, 2023
pulisher
Mar 30, 2023

Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis - MarketBeat

Mar 30, 2023
pulisher
Mar 30, 2023

BDRX News Today | Why did Biodexa Pharmaceuticals stock go down today? - MarketBeat

Mar 30, 2023
pulisher
Mar 28, 2023

Midatech PharmaDevelopment pipeline expands with MTD217 - research-tree.com

Mar 28, 2023

Finanzdaten der Biodexa Pharmaceuticals Plc Adr-Aktie (BDRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.05
price up icon 1.77%
$35.85
price down icon 0.53%
$21.32
price down icon 0.15%
$99.46
price down icon 1.19%
$108.80
price up icon 2.21%
biotechnology ONC
$246.51
price up icon 1.76%
Kapitalisierung:     |  Volumen (24h):